[Analysis of coagulation factor VIII inhibitor development related factors in hemophilia A patients.].
OBJECTIVE
To analyze the clinical features of hemophilia A (HA), and the factors associated with the factor VIII (FVIII) inhibitor development.


METHODS
One huandred and thirteen patients with HA were recruited in this retrospective study, among whom, 85 were treated with FVIII replacement therapy. The FVIII inhibitor levels and factors associated with the inhibitor development were correspondingly investigated in these 85 patients.


RESULTS
FVIII inhibitor developed in 28.24% of the 85 severe and moderate patients treated with FVIII. Factors of statistical significance (P < 0.05) associated with the low-titer FVIII inhibitor development were as follows: the first enduring adminstration of FVIII, the situation of the patients, and the high dose FVIII used in severe bleeding or major operation.


CONCLUSIONS
The development of FVIII inhibitor by Bethesda assay in Chinese hemophilia A patients is not rare, especially that with low-titer. Most of them are severe and moderate patients. The inhibitor development was associated with the following factors: the first adminstration of FVIII for more than 5 days, the severe or moderate conditions of patients, the high dose FVIII used in severe bleeding or major operation.
The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, The Key Laboratory of Thrombosis and Hemostasis of Ministry of Health, Suzhou 215006, China.
Lu-Lu
LL
Zhang
Zi-Qiang
ZQ
Yu
Wei
W
Zhang
Chang-Geng
CG
Ruan
D044466:Asian People; D005169:Factor VIII / Q000008:administration & dosage; D006467:Hemophilia A / Q000628:therapy; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D012189:Retrospective Studies
D005169:Factor VIII